Clinician Scientist in Tübingen – Twelve Months of Research Count Towards Specialist Training

How many months of research does Tübingen credit towards specialist training in 2026?

On 6 May 2026 the Faculty of Medicine in Tübingen and the Regional Medical Association of South Württemberg agreed that up to twelve months of patient-oriented research within a structured clinician scientist programme may be credited towards specialist training time. The conditions are a 36-month programme and a 50 percent release from clinical duties. The agreement runs until the end of 2029 and can be extended.

The review is project-specific rather than blanket. Faculty assessors, together with the training committee of the regional medical association, judge whether the research project is compatible with the requirements of specialist training. The faculty’s dean, Professor Stephan Zipfel, described the point of it in the press release of 29 May 2026 as follows: scientific findings are „not a sprint but a marathon“, and the agreement provides a tailwind along the way.

Specialist training lasts five to six years depending on the field. Twelve creditable months therefore amount to 17 to 20 percent of the total. That is not a symbolic figure. It is a year of one’s life at a stage when many doctors are planning a family and a career at the same time.

Why has research time so far not been credited automatically?

The (Model) Specialist Training Regulations of the German Medical Association in the 2018 version, last updated on 3 July 2026, provide in section 4(4) that interruptions to training do not count as training time. „Scientific assignments, where no training takes place“ are named explicitly. Interruptions of no more than six weeks per calendar year are exempt.

At first glance that contradicts the Tübingen agreement. It does not, and the resolution is worth reading carefully. First, the model regulations are only advisory; what is legally binding is the training regulation of the regional medical association you belong to. Second, the exclusion clause bites only where no training takes place during the research. With a 50 percent release that is precisely not the case: the other half of the working time remains clinical care under training conditions. Incidentally, the same wording as in the model regulations is found in the 2020 training regulations of the Baden-Württemberg Medical Association.

In its 2025 interim assessment of the clinician scientist programmes, the German Research Foundation names exactly this point as one of the central open tasks: uniform rules on the recognition by the regional medical associations of the competencies acquired during research time. As long as those are missing, the association district decides. Berlin recognises up to 18 months for the BIH Charité Clinician Scientist Programme; the programme started in 2011 with eight fellows, now counts more than 140 active participants and around 150 alumni, and the external evaluation appeared in May 2021.

How is a clinician scientist programme structured in practice?

Clinician scientist programmes are not scholarships but employment models. Part of the working time is contractually released for research and cross-financed through rotation posts, so that the hospital can absorb the gap in clinical care. Added to that are a structured curriculum, mentoring and central programme coordination. The German Research Foundation describes these elements as the minimum standard of its funding line.

In Tübingen the route is tiered. It begins with the Junior Clinician Scientist for doctors at the start of their specialist training, continues through the MINT-CS programme for translational work, and for now ends with the Advanced Clinician Scientist for qualified specialists, which according to the faculty provides for 30 percent research time over three years. Junior TüFF and TüFF Habil are complementary lines supporting women in science.

• protected research time of as a rule 50 percent, contractually guaranteed and cross-financed through rotation posts
• a curriculum covering methodology, statistics, study design and the fundamentals of clinical trials
• mentoring by one clinical and one scientific supervisor
• a defined research project with milestones and regular review
• onward prospects such as advanced programmes, junior research groups or professorships with a research component

Who funds clinician scientist programmes in Germany?

Since 2018 the German Research Foundation has funded a total of 23 clinician scientist programmes at faculties of medicine across two calls, 13 in the first round in 2018 and ten in the second round in 2022, with durations of up to five years. The Federal Ministry for Research, Technology and Space funds advanced programmes for the period after specialist certification; the relevant guideline was published on 24 September 2024.

Tübingen shows how much can come together at a single location. In April 2026 the Deutsches Ärzteblatt reported around ten million euros for two Tübingen programmes: roughly 7.9 million euros from the Federal Ministry for Research, Technology and Space for the ten-year programme „Medical Innovation through Synergy.2“ and 1.6 million euros from the German Research Foundation to continue MINT-CS.

Our own calculation, because this context is otherwise missing: the German Medical Faculty Association counts 40 voting faculties of medicine in Germany. Twenty-three DFG-funded programmes therefore correspond to around 58 percent of locations. Put differently: at roughly four in ten faculties there is no DFG-funded clinician scientist programme. The qualification here is that faculties may run their own or differently financed programmes; as far as our research goes, no complete public list of all programmes exists.

How research-intensive is German medicine in figures?

The Federal Statistical Office counted 1,571 habilitations in Germany for 2025, an increase of 0.4 percent on 2024. Of those, 911, or 58 percent, were in human medicine and health sciences, by some distance the largest share of any subject group. The proportion of women in this group was 36 percent, and the average age at habilitation across Germany was 42.

The subject dominates doctorates as well. Of the 212,400 doctoral candidates in 2024, around 28 percent were in human medicine and health sciences. On the care side: as at 31 December 2025 the German Medical Association records a total of 446,120 practising doctors, of whom 233,519 work in hospitals.

At first glance these figures look like a contradiction of the research-bottleneck thesis. My assessment of that, clearly marked as such: habilitations count titles, not protected time. In medicine a large share of this work is produced alongside clinical care, in evenings and at weekends. The average age of 42 is the most telling value in the whole dataset. It describes how long this dual path takes when nobody underwrites it structurally.

How do other countries combine research and specialist training?

Other health systems place the link at a different point in a career. The United States front-loads research through MD-PhD programmes before entry into practice, the United Kingdom integrates 25 and later 50 percent research time into specialist training, Switzerland funds a standalone MD-PhD phase, and the Netherlands interlocks it with the degree itself.

Behind these lines sit figures that make the price of each model visible. According to an analysis in JCI Insight from 2022, there are around 50 NIGMS-funded MD-PhD programmes in the United States and almost as many without NIH funding; in 2020, 620 MD-PhD graduations stood against 20,387 straight MD graduations, and the average time to completion rose from 6.69 years in the 1975 to 1984 cohort to 8.25 years in the 2005 to 2014 cohort. The report of the NIH Physician-Scientist Workforce Working Group of 4 June 2014 puts the share of research-active doctors at 1.5 percent of the medical profession; the average age of NIH-funded researchers holding an MD rose from 48 to 51 between 2003 and 2012. Early structured support has a measurable effect: those who had previously held a K award achieved a project funding success rate of 44.1 percent, against 9.2 percent without such prior support.

The United Kingdom shows the flip side of integration. The NIHR Academic Clinical Fellowship lasts up to three years, and up to four in general practice and dentistry, reserving 25 percent of the time for research; the clinical 75 percent counts towards specialist training as normal. The Medical Schools Council survey of 2025 counts 3,105 full-time equivalents of clinical academics in total, but a fall from 140 to 105 full-time equivalents in the under-36 age group. A Medical Research Council report from January 2025 therefore recommends increasing the number of permanent research posts by 40 a year over five years.

Switzerland has supported the MD-PhD since 1992 through a national scholarship programme, run jointly with the Swiss National Science Foundation until 2024 and today carried by the Swiss Academy of Medical Sciences. In the 2025 call, 18 of 40 applications were approved, with a total volume of 3,028,273 francs. At Amsterdam UMC the MD-PhD track starts in the first master’s year; the master’s degree must be completed before the defence.

Is the clinician scientist route also open with a degree from elsewhere in the EU?

Yes. Article 21(1) of Directive 2005/36/EC obliges every member state to recognise the evidence of formal qualifications listed in Annex V. Article 24(2) sets the minimum requirement at at least five years of study and at least 5,500 hours of theoretical and practical training. With the German medical licence (Approbation) in hand, access to specialist training, and therefore to the programmes, is the same as after a German degree.

I studied dentistry in Sofia from 2015 to 2021 and later had my own diploma recognised, in Switzerland through the Medical Professions Commission MEBEKO. I am not a clinician scientist, and I will not pretend to have walked this route myself. What I took away from the recognition procedure fits here nonetheless: the European framework does not ask where you trained but whether the training meets the minimum requirements. That single distinction decides more about career paths than any ranking.

The second building block is the doctorate. The doctoral regulations of the Tübingen Faculty of Medicine for the Dr. med. and Dr. med. dent. require in section 3(1) a degree completed in Germany as a general rule, but make clear in subsection 1(b) that degrees from foreign universities can be recognised if they are equivalent. In cases of doubt the Central Office for Foreign Education can be consulted, and language skills must as a rule be evidenced at C1 level. For EU degrees covered by automatic recognition, equivalence is in substance already secured under European law.

One area of uncertainty remains, stated honestly: doctoral regulations differ from faculty to faculty, and some require additional evidence. Studying in Sofia, Plovdiv, Pécs or Zagreb does not rule out an academic career in Germany, but it does not replace reading the regulations of the faculty you have in mind. If you want to know which locations and study models fit such a goal, you can arrange a free consultation with us.

What can students do early on for a research career?

The clinician scientist route does not begin with an application for a programme place but considerably earlier. Anyone who wants to keep the option open chooses a doctoral project with a clinical or translational focus, builds methodological skills, and pays attention when taking a first training post to how the responsible regional medical association recognises research time.

• choose a doctoral project with a clinical or translational focus rather than treating it as a formality
• build methodological skills: statistics, study design, the fundamentals of good clinical practice
• do clinical placements deliberately at research-active hospitals and build contacts there
• aim for first publications or conference contributions, including as a co-author
• before taking a first training post, check whether the location has a structured programme and how the association recognises research time

The last point has become more important since the Tübingen agreement, because recognition practice has turned into a genuine criterion for choosing between hospitals. Anyone planning both, specialist training and research, should raise this question at interview. It costs three sentences and can be worth a year.

This article reflects the position as at August 2026 and is intended as general information; it does not replace legal advice in an individual case. What is decisive are the training regulations of the responsible regional medical association in force at the time and the doctoral regulations of the faculty concerned.